Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma

Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma

The use of immune checkpoint inhibitors (ICIs) in combination with tyrosine kinase inhibitors or other ICIs has significantly improved the prognosis for patients with mccRCC. This marks a major milestone in the treatment of mccRCC. Nonetheless, most patients will discontinue first-line therapy. In t...

Full description

Bibliographic Details
Main Authors: Alessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, Marco Donatello Delcuratolo, Chiara Pisano, Isabella Saporita, Mariangela Calabrese, Federica Maria Carfì, Marcello Tucci, Consuelo Buttigliero
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Journal of Clinical Medicine
Subjects:
kidney cancer
metastatic clear cell renal cell carcinoma
immuno-oncology
treatment
immune checkpoint inhibitors
tyrosine kinase inhibitors
Online Access:https://www.mdpi.com/2077-0383/13/2/307

Internet

https://www.mdpi.com/2077-0383/13/2/307

Similar Items